Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or MDS with high-risk features and have had a stem cell transplant (donor) within the last few months.
- Your leukemia or MDS cells tested positive for CD123 (a protein) before your transplant.
- After transplant, your disease is in remission or has only a small amount of leftover disease.
- Your blood counts (neutrophils and platelets) are recovering well and you are not on high doses of steroids for graft-versus-host disease (GVHD).
- You are between 18 and 75 years old and have a good overall health status (ECOG score 0-2, meaning you can care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.